RXAIPO Pharma, AI, Public Opportunities

Mihir Otia

AI, healthcare, investing and the future of wealth and careers. Faceless daily breakdowns of the trends that matter.

  1. 1h ago

    AI: ~60% of Kids in a Brain Cancer Trial May Not Have Needed Full-Dose Radiation

    A Dana-Farber-led team built MANTIS, an AI that reads DNA methylation from children's brain tumours (a test already used for diagnosis) and predicts each child's survival over 10 years. Built on data from 2,786 patients and tested on 898 children from three clinical trials it never saw, it significantly beat current clinical risk markers. Re-analysing a randomised trial of lower-dose radiation (170 children aged 3–7), it identified ~60% (104 children) for whom the lower dose showed no detectable survival disadvantage, inside a trial where lower dose did worse overall. Published 3 Nov 2026 in Nature Genetics. Fine print: retrospective, small groups, radiation dose only, prospective trials needed. Not a reason to change any child's treatment. Get the daily signal on AI, healthcare and investing: newsletter link in the pinned comment. Source: Stefan et al., Nature Genetics (2026), DOI 10.1038/s41588-026-02815-4. Not medical or investment advice. #Shorts #HealthAI #AI #PrecisionMedicine #ChildhoodCancer #Biotech #Investing

  2. 1d ago

    An AI just out predicted hearts experts

    An AI read 27,382 heart MRI scans, and its ejection-fraction measurements predicted who would die slightly but significantly better than expert clinicians' measurements, in 2–3 seconds per patient vs around 13 minutes. Published 2 Nov 2026 in The Lancet Digital Health (City St George's, University of London + UCL). The twist: it graded AI and doctors against survival, not against each other. Fine print: retrospective, marginal edge, clinician oversight still essential. Get the daily signal on AI, healthcare and investing: newsletter link in the pinned comment. Source: Joy et al., The Lancet Digital Health (2026), DOI 10.1016/j.landig.2026.101042. Not medical or investment advice. #Shorts #HealthAI #AI #Cardiology #MedicalImaging #HealthTech #Investing

  3. 4d ago

    AI Company hired a 1 men led pharma company with 11 labs run by an AI

    Anthropic disclosed on 27 Oct 2026 that it acquired Mithril Medicine, a biotech with one full-time employee who used Claude to coordinate 11 outside labs. Idea to mouse proof of principle in under 18 months for a rare childhood muscular dystrophy; human trials possible from late 2028, Anthropic says. Fine print: 7 vs 4 mice, not randomised, not peer reviewed, and Anthropic owns the drug. Plus six pharma/biotech partners and an S-1 filed the day before. Free daily briefing: newsletter link in channel bio. Sources: Anthropic (27 Oct 2026), R&D World, The Next Web, NDTV, European Pharmaceutical Review. #AI #Biotech #Anthropic #Claude #DrugDiscovery #Investing #Shorts #RXAIPO

  4. 4d ago

    AI just failed a test that actually matters: how much of a drug to give.

    Doximity tested 9 widely used AI models with 8,000+ real dosing questions. At least 2.3% of dosing claims were wrong. 43.8% of those errors were serious or potentially lethal. The biggest failure: ignoring age, kidney function and drug interactions, even when the question included them. Newly approved drugs had 5x the odds of an error. Their answer is DoseCheck, a rule-based check against FDA labels that they say is 99.9% accurate. Remember who is talking: the company that found the problem sells the fix. The signal: 81%+ of US doctors already use AI. In healthcare, the moat isn't the smartest model. It's the one that can prove it's safe. Comment SIGNAL and I'll DM you the full breakdown plus tomorrow's briefing. Save this for the next time someone says AI is ready to replace your doctor. Sources: Healthcare Dive, Doximity (29 Oct 2026). #AI #HealthcareAI #MedicalAI #DigitalHealth #Pharma #PatientSafety #HealthTech #ArtificialIntelligence #FutureOfMedicine #Biotech #Investing #DOCS #Doctors #Pharmacist #RXAIPO

  5. Oct 13

    Novartis’ $7.8B mRNA Deal with Abogen: What It Means | Money Meets Medicine

    Novartis has signed a licensing deal with Chinese biotech Abogen Biosciences worth up to $7.8 billion for ABO2203, an mRNA-encoded T-cell engager aimed at autoimmune disease. We break down the $575 million upfront, the in-vivo production approach, early clinical signals, why the risk profile looks different, and the larger pattern of big pharma writing large checks for Chinese RNA platforms. This is the shift: mRNA moving beyond vaccines into chronic disease and immune reset. Subscribe for more deals where money meets medicine. Show notes: • Deal structure and numbers • How ABO2203 works (mRNA-encoded CD19xCD3 T-cell engager) • Early data and safety signals • Novartis’s autoimmune focus • Investing takeaways and the broader China biotech licensing trend

  6. Sep 30

    Healthcare's ChatGPT Moment: AI, Pharma & The Future of Medicine

    Artificial Intelligence is no longer a future healthcare trend. It's already being deployed across healthcare organisations, research labs and pharmaceutical companies. In this episode, we explore how AI is reshaping healthcare, drug discovery and the future of medicine. Topics covered: • Why healthcare is embracing AI • OpenAI's move into healthcare • How pharmaceutical companies are integrating AI • The future of drug discovery • Healthcare investment opportunities • Risks, regulation and ethical considerations • What the next decade of medicine could look like Whether you're a healthcare professional, investor, student or simply curious about the future, this episode breaks down one of the biggest shifts happening in healthcare today. Money Meets Medicine explores the intersection of: 💊 Healthcare 🤖 Artificial Intelligence 📈 Investing 🧬 Biotechnology 🌍 Future Trends Follow the show for weekly discussions on healthcare innovation, market trends, investing insights and the future of medicine.

  7. 03/27/2023

    AI & NUCLEAR PHARMACY- Trustworthiness of AI in Nuclear Medicine

    This episode is also available as a blog post: http://mihirotia.data.blog/2023/03/26/ai-nuclear-pharmacy-trustworthiness-of-ai-in-nuclear-medicine/

  8. 03/08/2023

    Bridging Gender Gap Wtihin AI

    This episode is also available as a blog post: http://mihirotia.data.blog/2023/03/08/bridging-gender-gap-wtihin-ai/

    Bridging Gender Gap Wtihin AI
See All (26)

About

AI, healthcare, investing and the future of wealth and careers. Faceless daily breakdowns of the trends that matter.

Information